Business
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge ...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"\n\n\n\n Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge\n \n\n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n\n\n\n\n\n Canada NewsWire\n \n\n\n\n\n\n\n USA\n \n News Group\n \n\n\n News Commentary\n \n\n\n\n\n Issued on behalf of Oncolytics Biotech Inc.\n \n\n\n\n\n\n VANCOUVER, BC\n \n\n ,\n \n\n March 8, 2025\n \n\n /CNW/ -- As the global cancer crisis intensifies, the demand for breakthrough treatments is reaching new heights.\n \n Statista\n \n data projects a 20% rise in annual cases by 2030 and a\n \n staggering 75% increase by 2050\n \n . According to the\n \n World Health Organization (WHO)\n \n , breast cancer cases are\n \n projected to rise by nearly 40% by 2050\n \n . Despite the concerning trends in cancer incidence, 2025 has seen key advancements from biotech companies at the forefront of oncology research, with\n \n Oncolytics Biotech Inc.\n \n (NASDAQ: ONCY) (TSX: ONC),\n \n Exelixis, Inc.\n \n (NASDAQ: EXEL),\n \n Cardiff Oncology, Inc.\n \n (NASDAQ: CRDF),\n \n ALX Oncology Holdings Inc.\n \n (NASDAQ: ALXO), and\n \n Verastem, Inc.\n \n (NASDAQ: VSTM) continuing to push the boundaries of cancer treatment.\n \n\n The article continued: Within a\n \n new research report\n \n on the Global Oncology Market from\n \n Vision Research Reports\n \n , cancer therapies are projected to surpass\n \n US$903.81 billion\n \n by 2034, growing at a 10.9% CAGR along the way. The\n \n World Economic Forum\n \n is optimistic, recently touting\n \n 12 new breakthroughs\n \n in the fight against cancer.\n \n\n\n Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC)\n \n , a clinical-stage company focused on immunotherapy for cancer, has just released its Q4 and full-year 2024 financial results, providing investors with a clearer picture of its progress as it moves toward potential future\n \n FDA\n \n approvals for its lead drug, pelareorep, a promising immunotherapy designed to help the immune system recognize and destroy cancer cells more effectively.\n \n\n \"With multiple clinical trials surpassing expectations in 2024, 2025 is shaping up ...